Google and Venter Mum on Collaboration Reports


By Juan Carlos Perez IDG News Service

Google and the J. Craig Venter Institute are playing down highly publicized reports of a collaboration reported in a recently published book.

David Vise and Mark Malseed wrote in The Google Story, published in November, that Google founders Sergey Brin and Larry Page and genome sequencer J. Craig Venter had started collaborating in the area of genetics research in early 2005.

However, asked to comment on those plans, both Google and the Venter Institute remained tight-lipped.

“Google has been exploring applications of our technologies to various scientific fields, including biology. We have no products to announce or information to share at this time,” a Google spokesman wrote via e-mail.

“At the Venter Institute, there isn’t a project under way of that nature that ran in David Vise’s book, so we don’t have anything to contribute at this time,” said an institute spokeswoman.

Catalogue of Genes
The concluding chapter of The Google Story is devoted to the Google founders’ “ambitious long-term plans for Google’s expansion into the fields of biology and genetics and the fusion of science, medicine, and technology.”

Vise recounts discussions that both Brin and Page held with Venter in 2005 and that eventually led to Google making computing resources and engineers available to Venter.

“We need to use the largest computers in the world,” Venter told the authors. “Larry and Sergey have been excited about our work and about giving us access to their computers and their algorithm guys and scientists to improve the process of analyzing data.”

Venter described the collaboration’s focus as generating “a gene catalogue to characterize all the genes on the planet and understand their evolutionary development,” Venter told Vise.

“People will be able to log on to a Google site using search capacities and have the ability to understand things about themselves as they change in real time,” Venter was quoted as saying in the book.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.